GALK1 and cystitis: First, validation of NNMT, GALK1, and HTRA1 and other candidates tightly correlated with BCa stage needs to be performed using larger patient cohorts of BCa including benign conditions such as cystitis, samples with hematuria, as well as other tumors from the urogenital tract (prostate, and renal).